Surgery Following Induction (Neoadjuvant) Therapy with Pembrolizumab in Lung Adenocarcinoma with High PD-L1 Expression
Article Sidebar
Main Article Content
Abstract
A case of a patient with lung adenocarcinoma with high PD-L1 expression initially not eligible to surgery due to advanced stage is reported. After induction with pembrolizumab, bilateral surgery was perfomed. Invasive staging is necessary to define the clinical stage and is particularly important in the case of proceeding to post-induction surgery due to the high rate of false negatives of imaging methods. Molecular study including mutations and membrane expression molecules of biopsies is of utmost importance to offer patients the best treatments. The use of targeted therapies instead of conventional chemotherapy has improved survival in lung cancer. Surgery should be initially considered in strategic treatment planning.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Ginsberg RJ. Neoadjuvant (induction) treatment for non-small cell lung cancer. Lung Cancer Amst Neth 1995;12 Suppl 2:S33-40.
Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N Engl J Med 2016;375(19):1823–33. Doi: 10.1056/NEJMoa1606774.
Mok TSK, Wu YL, Kudaba I et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393(10183):1819–30. Doi: 10.1016/S0140-6736(18)32409-7.
Evans NR, Li S, Wright CD, Allen MS, Gaissert HA. The impact of induction therapy on morbidity and operative mortality after resection of primary lung cancer. J Thorac Cardiovasc Surg 2010;139(4):991-996.e1-2.
Travis WD, Dacic S, Wistuba I et al. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J Thorac Oncol 2020;15(5):709–40. Doi: 10.1016/j.jtho.2020.01.005.
Bueno R, Richards WG, Swanson SJ et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000;70(6):1826–31. Doi: 10.1016/s0003-4975(00)01585-x.
De Cabanyes Candela S, Detterbeck FC. A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. J Thorac Oncol 2010;5(3):389–98. Doi: 10.1097/JTO.0b013e3181ce3e5e.